Business Context and Reporting Period
Company: Inovio Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2026
Event: Entry into a Material Definitive Agreement regarding the amendment of outstanding Series A Warrants.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate action regarding warrant terms.
Material Changes
- Warrant Expiration Extension: The Company amended its outstanding Series A Warrants (issued July 7, 2025) to extend the expiration date from January 28, 2026, to March 31, 2026.
- Warrant Details: The warrants are exercisable for up to 13,564,268 shares of Common Stock or Pre-Funded Warrants.
- Exercise Price: $1.75 per share (or $1.749 per Pre-Funded Warrant).
- Trigger Event: The original expiration was tied to the 30-day period following the public announcement of FDA acceptance of a Biologic License Application for INO-3107.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or new risk factors. The primary contingency noted is the regulatory status of INO-3107, which originally dictated the warrant expiration timeline. A prospectus supplement amendment will be filed with the SEC.
Investor Verification Checklist
- Verify the exact number of outstanding Series A Warrants and Pre-Funded Warrants as of the filing date.
- Confirm the current market price of INO common stock relative to the $1.75 exercise price to assess dilution risk.
- Review the status of the Biologic License Application for INO-3107 with the FDA.
- Examine the full text of the Amendment (Exhibit 4.1) for any additional covenants or conditions not summarized in the 8-K.